Please select the option that best describes you:
Do you change systemic endocrine therapy for a patient who progresses only in the brain after SRS for metastatic HR+ breast cancer?
She has no other site of disease progression and has been on an aromatase inhibitor (progressed in the CNS while on a study with adjuvant abemaciclib).
Answer from: Medical Oncologist at Community Practice
No, I would continue the same hormonal therapy until systemic progression. The brain is a sanctuary site. Disappointing that abemaciclib did not prevent since it crosses b-b barrier.
Sign in or Register to read more